查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1433409

全球新藥輸送系統(NDDS)市場 2023-2030

Global New Drug Delivery Systems (NDDS) Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 115 Pages | 商品交期: 2-3個工作天內

價格

預計全球 NDDS 市場在預測期內（2024-2031年）將以 21.6%的CAGR成長。市場的成長歸因於對標靶治療的需求不斷成長。由於與糖尿病相關的風險增加，對治療心血管問題的更具體和更有針對性的藥物的需求不斷增加。 NDDS 提供了一種可能性，允許將藥物直接輸送到受影響的部位，減少全身副作用，同時提高治療效果。據美國國家醫學研究所表示，2021年 10月，這項研究涵蓋了來自不同地區的 3,908 名 40 歲至 74 歲的成年人。對他們的心臟代謝特徵進行了評估，並對其雙側頸動脈進行了檢查。頸動脈斑塊和糖尿病（DM）的盛行率分別為34.4%和10.7%。當修正其他傳統危險因子時，糖尿病患者的頸動脈斑塊、斑塊總數、最大直徑狹窄（30%）和斑塊的盛行率較高（頸動脈斑塊多變量調整OR 1.60，斑塊總數2.06，斑塊總數1.3）與非糖尿病對照組相比，最大直徑狹窄及斑塊評分為 2.03。

細分市場前景

全球 NDDS 市場根據 NDDS 的給藥途徑和模式進行細分。依給藥途徑，市場可細分為口服給藥系統、注射給藥系統、肺部給藥系統、經皮給藥系統等。此外，根據NDDS的模式，市場細分為標靶給藥系統、受控給藥系統、調製給藥系統等。注射給藥系統子類別預計將佔據給藥途徑領域的很大一部分市場佔有率。該成長可歸因於全球疫苗接種活動數量的不斷增加，推動了對儀器的需求。

預計口服給藥系統細分市場將在全球 NDDS 市場中佔據相當大的佔有率

在給藥途徑中，數位口服給藥系統細分市場預計將在全球 NDDS 市場中佔據相當大的佔有率。細分市場的成長歸因於對有效口服療法的需求。對癌症、心血管、傳染病和糖尿病等多種疾病類別更有效的口服藥物的渴望是主要的驅動力。 EUDRATEC SoluFlow 開發增強型口服藥物的能力符合市場需求。例如，2022年3月，Evonik推出了新的EUDRATEC技術，以提高口服小分子的溶解度。 EUDRATEC SoluFlow 是一種基於乳液的加工技術，克服了溶解度限制，可以開發針對癌症、心血管、傳染病和糖尿病等多種疾病的創新口服療法。

區域展望

全球 NDDS 市場根據地理位置進一步細分，包括北美（美國和加拿大）、歐洲（英國、義大利、西班牙、德國、法國和歐洲其他地區）、亞太地區（印度、中國、日本、韓國、亞洲其他地區）以及世界其他地區（中東和非洲以及拉丁美洲）。其中，由於醫療保健產業受益於人口成長和政府支持，預計北美將在全球市場中佔據顯著佔有率。

北美地區預計全球新藥輸送系統（NDDS）市場複合CAGR顯著成長

在所有地區中，北美地區預計在預測期內將以相當大的CAGR成長。區域成長歸因於該地區對有效治療的需求不斷增加。長期呼吸道疾病的發生率不斷上升，導致對更有效治療方法的高需求。客製化的藥物輸送系統有可能顯著改善治療結果並降低疾病嚴重程度，滿足需求。根據MDPI 的資料，到2023年8月，包括氣喘和慢性阻塞性肺病（COPD）在內的慢性發炎性呼吸系統疾病對全球產生重大影響，影響數百萬人，導致肺部疾病發病率和死亡率上升。2020年，全球有超過 3 億人受到氣喘和慢性阻塞性肺病的影響，成為第三大死因，迫切需要更有效的治療方法。近年來，針對藥物傳遞系統，例如基於奈米顆粒的方法、吸入皮質類固醇、新型生物製劑、基因治療和個人化醫療，在提高藥物療效和減少副作用方面顯示出了希望。透過利用奈米粒子封裝藥物並將其直接遞送至肺部的特定細胞，研究人員目的是提高藥物遞送效率，同時最大限度地減少脫靶效應，提供持續釋放和延長治療效果的潛力。

市場參與者展望

服務NDDS市場的主要公司包括拜耳公司、波士頓科學公司、強生服務公司和默克公司等。市場參與者透過各種策略（包括併購、夥伴關係、合作、融資和新產品發布），為市場成長做出了巨大貢獻，以保持市場競爭力。例如，2022年6月，EVERSANA與Accord BioPharma合作推出了CAMCEVI（leuprolide）42mg注射乳劑，用於治療成人晚期攝護腺癌。

報告涵蓋：

  • 2023年市場價值資料分析及2031年預測。
  • 每個細分市場的年化市場收入（百萬美元）。
  • 主要地理區域的國家分析。
  • 在全球 NDDS 市場營運的主要公司。根據現有資料，報告中還提供了與新產品發布相關的資訊以及相關新聞。
  • 透過確定未來強勁成長的關鍵細分市場來分析業務策略。
  • 市場進入和市場擴張策略分析。透過識別市場中「誰的立場」來制定競爭策略。

目錄

第1章 報告摘要

  • 目前行業分析及成長潛力展望
  • 研究方法和工具
  • 市場區隔
    • 依細分
    • 依地區

第2章 市場概述與見解

  • 報告範圍
  • 分析師見解和當前市場趨勢
    • 主要發現
    • 建議
    • 結論

第3章 競爭格局

  • 主要公司分析
  • Abbott Laboratories
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Amgen Inc. and Amgen USA Inc.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • AstraZeneca
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • 關鍵策略分析

第4章 市場細分

  • 依給藥途徑分類的全球新藥物輸送系統（NDDS）市場
    • 口服給藥系統（DDS）
    • 注射給藥系統（DDS）
    • 肺部給藥系統（DDS）
    • 經皮給藥系統（DDS）
    • 其他（鼻腔給藥系統（DDS）及植入式給藥系統（DDS））
  • 按 NDDS 模式分類的全球新藥物輸送系統（NDDS）市場
    • 標靶給藥系統
    • 受管制藥物傳輸系統
    • 調製藥物輸送系統
    • 其他（基於生物製劑的藥物傳輸系統和基於奈米給藥途徑的藥物傳輸系統）

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 歐洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 世界其他地區

第6章 公司簡介

  • Bayer AG
  • Boston Scientific Corp.
  • Bristol Myers Squibb（BMS）
  • Celgene Corp.
  • At F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck KGaA,
  • Novartis International AG
  • Pfizer Inc.
  • Assertio Holdings, Inc.
  • Gilead Sciences, Inc
  • Medtronic Pvt. Ltd.
  • Becton, Dickinson, and Co.
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Cipla Ltd.
Product Code: OMR2028062

Global New Drug Delivery Systems (NDDS) Market Size, Share & Trends Analysis Report by Route of Administration (Oral Drug Delivery Systems (DDS), Injectable Drug Delivery Systems (DDS), Pulmonary Drug Delivery Systems (DDS), Transdermal Drug Delivery Systems (DDS), and Others ), and by Mode of NDDS (Targeted Drug Delivery Systems, Controlled Drug Delivery Systems, Modulated Drug Delivery Systems, and Others) Forecast Period (2024-2031)

The global NDDS market is anticipated to grow at a CAGR of 21.6% during the forecast period (2024-2031). The market's growth is attributed to the growing demand for targeted therapies. Based the increased risks associated with diabetes, there is rising demand for more specific and focused medicines for managing cardiovascular problems. NDDS provides a possibilities by allowing drugs to be delivered directly to afflicted locations, decreasing systemic side effects while increasing the effectiveness of therapy. According to the National Institute of Medicine, in October 2021, the study included 3,908 adults aged 40 to 74 years from a wide range of regions. Their cardiometabolic profiles were evaluated, and its carotid arteries were examined bilaterally. The prevalence rates of carotid plaque and diabetic mellitus (DM) were 34.4% and 10.7%, respectively. when modifying for other conventional risk factors, DM patients had higher prevalence rates of carotid plaque, total plaque number, maximum diameter stenosis (30%), and plaque (multivariable-adjusted OR 1.60 for carotid plaque, 2.06 for total plaque number, 1.3 for maximum diameter stenosis, and 2.03 for plaque score) than non-DM controls.

Segmental Outlook

The global NDDS market is segmented on the route of administration, and mode of NDDS. Based on the route of administration, the market is sub-segmented oral drug delivery systems, injectable drug delivery systems, pulmonary drug delivery systems, transdermal drug delivery systems, and others. Furthermore, on the basis of mode of NDDS, the market is sub-segmented into targeted drug delivery systems, controlled drug delivery systems, modulated drug delivery systems, and others. The Injectable drug delivery systems subcategory is expected to capture a significant portion of the market share within the route of administration segment. The growth can be attributed to the growing number of vaccination's drives across the globe propelling the demand for instruments.

The Oral Drug Delivery Systems Sub-Segment is Anticipated to Hold a Considerable Share of the global NDDS Market

Among the route of administration, the digital oral drug delivery systems sub-segment is expected to hold a considerable share of the global NDDS market. The segmental growth is attributed to the demand for effective oral therapies. The desire for more effective oral medicines in a variety of disease categories, including cancer, cardiovascular, infectious, and diabetes, is a major driving force. EUDRATEC SoluFlow's ability to enable the development of enhanced oral pharmaceuticals aligns with a market demand. For instance, in March 2022, Evonik launched new EUDRATEC technology to improve solubility of oral small molecules. The EUDRATEC SoluFlow, an emulsion-based process technique, overcomes solubility constraints, allowing the development of innovative oral therapies for a variety of diseases such as cancer, cardiovascular, infectious, and diabetes.

Regional Outlook

The global NDDS market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, North America is anticipated to hold a prominent share of the market across the globe, owing to the healthcare industry benefits from a growing population and government support.

The North America Region is Expected to Grow at a Significant CAGR in the global New Drug Delivery Systems (NDDS) Market

Among all regions, North America region is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the increasing demand for effective treatments across the region. The rising incidence of long-term respiratory diseases has resulted in a high demand for more effective therapies. Customized drug delivery systems have the potential to significantly improve treatment outcomes and reduce disease severity, thus satisfying the need. According to MDPI, in August 2023, the chronic inflammatory respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD), have a significant global impact, affecting millions of people and contributing to the rise in lung disease morbidity and mortality. With over 300 million individuals globally affected by asthma and COPD becoming the third leading cause of death in 2020, there is a pressing need for more effective treatments. In recent years, targeted drug delivery systems, such as nanoparticle-based approaches, inhaled corticosteroids, novel biologicals, gene therapy, and personalized medicine, have shown promise in improving drug efficacy and reducing side effects. By utilizing nanoparticles to encapsulate and deliver drugs directly to specific cells in the lungs, researchers aim to enhance drug delivery efficiency while minimizing off-target effects, offering potential for sustained release and prolonged therapeutic effects.

Market Players Outlook

The major companies serving NDDS market includes Bayer AG, Boston Scientific Corp., Johnson & Johnson Services, Inc., and Merck KGaA, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in June 2022, EVERSANA, and Accord BioPharma, partnered to launched CAMCEVI (leuprolide) 42mg injection emulsion for the treatment of advanced prostate cancer in adults.

The Report Covers:

  • Market value data analysis of 2023 and forecast to 2031.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global NDDS market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies. Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Abbott Laboratories
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Amgen Inc. and Amgen USA Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. AstraZeneca
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global New Drug Delivery Systems (NDDS) Market by Route of Administration
    • 4.1.1. Oral Drug Delivery Systems (DDS)
    • 4.1.2. Injectable Drug Delivery Systems (DDS)
    • 4.1.3. Pulmonary Drug Delivery Systems (DDS)
    • 4.1.4. Transdermal Drug Delivery Systems (DDS)
    • 4.1.5. Others (Nasal Drug Delivery Systems (DDS), and Implantable Drug Delivery Systems (DDS))
  • 4.2. Global New Drug Delivery Systems (NDDS) Market by Mode of NDDS
    • 4.2.1. Targeted Drug Delivery Systems
    • 4.2.2. Controlled Drug Delivery Systems
    • 4.2.3. Modulated Drug Delivery Systems
    • 4.2.4. Others (Biologics-Based Drug Delivery Systems, and NanoRoute of Administration -Based Drug Delivery Systems)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Bayer AG
  • 6.2. Boston Scientific Corp.
  • 6.3. Bristol Myers Squibb (BMS)
  • 6.4. Celgene Corp.
  • 6.5. At F. Hoffmann-La Roche Ltd.
  • 6.6. GlaxoSmithKline PLC
  • 6.7. Johnson & Johnson Services, Inc.
  • 6.8. Merck KGaA,
  • 6.9. Novartis International AG
  • 6.10. Pfizer Inc.
  • 6.11. Assertio Holdings, Inc.
  • 6.12. Gilead Sciences, Inc
  • 6.13. Medtronic Pvt. Ltd.
  • 6.14. Becton, Dickinson, and Co.
  • 6.15. Teva Pharmaceutical Industries Ltd.
  • 6.16. Mylan N.V.
  • 6.17. Cipla Ltd.

LIST OF TABLES

  • 1. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2023-2031 ($ MILLION)
  • 2. GLOBAL ORAL DRUG DELIVERY SYSTEMS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 3. GLOBAL INJECTABLE DRUG DELIVERY SYSTEMS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 4. GLOBAL PULMONARY DRUG DELIVERY SYSTEMS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 5. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 6. GLOBAL OTHER DRUG DELIVERY SYSTEMS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 7. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY MODE OF NDDS, 2023-2031 ($ MILLION)
  • 8. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) BY TARGETED MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 9. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) BY CONTROLLED MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 10. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) BY MODULATED MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 11. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) BY OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 12. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 13. NORTH AMERICAN NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
  • 14. NORTH AMERICAN NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION , 2023-2031 ($ MILLION)
  • 15. NORTH AMERICAN NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY MODE OF NDDS, 2023-2031 ($ MILLION)
  • 16. EUROPEAN NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
  • 17. EUROPEAN NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION , 2023-2031 ($ MILLION)
  • 18. EUROPEAN NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY MODE OF NDDS, 2023-2031 ($ MILLION)
  • 19. ASIA-PACIFIC NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
  • 20. ASIA-PACIFIC NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION , 2023-2031 ($ MILLION)
  • 21. ASIA-PACIFIC NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY MODE OF NDDS, 2023-2031 ($ MILLION)
  • 22. REST OF THE WORLD NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 23. REST OF THE WORLD NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION , 2023-2031 ($ MILLION)
  • 24. REST OF THE WORLD NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY MODE OF NDDS, 2023-2031 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SHARE BY ROUTE OF ADMINISTRATION, 2023 VS 2031(%)
  • 2. GLOBAL ORAL DRUG DELIVERY SYSTEMS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 3. GLOBAL INJECTABLE DRUG DELIVERY SYSTEMS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 4. GLOBAL PULMONARY DRUG DELIVERY SYSTEMS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 5. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 6. GLOBAL OTHER DRUG DELIVERY SYSTEMS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 7. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SHARE BY MODE OF NDDS, 2023 VS 2031(%)
  • 8. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) BY TARGETED MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 9. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) BY CONTROLLED MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 10. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) BY MODULATED MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 11. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) BY OTHERS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 12. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 13. US NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
  • 14. CANADA NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
  • 15. UK NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
  • 16. FRANCE NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
  • 17. GERMANY NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
  • 18. ITALY NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
  • 19. SPAIN NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
  • 20. REST OF EUROPE NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
  • 21. INDIA NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
  • 22. CHINA NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
  • 23. JAPAN NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
  • 24. SOUTH KOREA NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
  • 25. REST OF ASIA-PACIFIC NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
  • 26. REST OF THE WORLD NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)